Safety of single low dose primaquine in Senegal.
Not Applicable
Recruiting
- Conditions
- Malaria
- Registration Number
- PACTR201411000937373
- Lead Sponsor
- niversity Cheikh Anta DIOP of Dakar, Department of Medical Parasitology.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
1. Adult patients with acute uncomplicated P. falciparum malaria;
2. P. falciparum monospecific infection with parasite density ranged from 1000 to 100 000 trophozoite/¿L.
3. Willingness to participate in the planed study investigations and to remain in the study area for the duration of the study;
4. Participants informed consent;
5. Absence of known chronic illness such as hypertension, diabetes, renal and liver disease.
Exclusion Criteria
1. Known allergy to the study medications;
2. Presence of severe anaemia (haemoglobin < 8 g/dl) at enrolment;
3. Pregnancy, or breastfeeding.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean haemoglobin difference from day 0 to day 7 after treatment with ACT and primaquine.
- Secondary Outcome Measures
Name Time Method Mean haemoglobin level at day 14 of follow up in each treatment arm.;Mean haemoglobin level at day 28 of follow up in each treatment arm.